A PHASE 2 MULTICENTER MULTINATIONAL RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY EFFICACY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF ESK 001 IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Systemic Lupus Erythematosus
  • Age: Between 18 Year(s) - 70 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Able and willing to provide written informed consent (signed and dated) to participate in this study and comply with all requirements in the study protocol
    2. Diagnosed with SLE =6 months prior to screening
    3. Currently receives at

You may not be eligible for this study if the following are true:

    1. Current or history within 1 year of screening of alcohol or drug abuse (excluding cannabis) based on Investigator’s clinical judgment.
    2. Pregnant, lactating, or planning to get pregnant during the study period and for 1 month after study


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.